The world’s largest drug maker Pfizer's first biosimilar (a medicine comparable to the original biotech drug) deal with India’s Biocon will trigger a new wave of outsourcing deals and acquisitions by multinational drug makers in India.Domestic companies that may benefit are believed to include biotech specialists and vaccine makers such as Panacea Biotec, Reliance Life Sciences, Bharat Biotech, BV Corp and Serum Institute of India, beside drug majors such as Wockhardt, Dr Reddy's Laboratories, Intas Biopharmaceuticals and Lupin, which are developing a large portfolio of biotech drugs.
The generic opportunity for biotech drugs such as EPO (for chemotherapy and renal failure), GCSF (prescribed to make more white blood cells during cancer treatment), Interferon Alpha (for Hepatitis C and renal failure), Interferon Beta (to treat multiple sclerosis, a chronic disease that affects central nervous system) and human insulin is estimated at $7 billion in
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |